CEO Ergen: we have done business with Google in the past - cnbc interview
- we have as much downlink spectrum as Verizon
- reiterates talking with everyone on their spectrum holdings (honestly dont know what we are going to do at this point to maximize long term value)
The math behind Heinz/Kraft {http://blogs.ft.com/lex-live/2015/03/25/the-math-behind-heinzkraft/}
Missing from the press release on the Kraft Heinz deal is just how much explicit value Kraft shareholders are getting. It’s an odd structure where Kraft gets 49 per cent of the new company PLUS a one-time dividend of $16.50.
Kraft shares have traded up to more than $80.
Here’s the simple arithmetic shareholders are doing:
Fed's Lockhart (moderate, FOMC voter): Optimistic that the economy is gaining strength despite slow start in 2015 - NY Times interview
- The slowness in the first quarter obviously raises concerns that were going to see a continuing or persistent slowdown, but thats not my base case view. My base case view is that well see a rebound in the second and third quarter and beyond and that well stay on the basic track that has been our story, our narrative here, for the last year or more. And that is a 2.5 percent to 3 percent growth rate with continuing improvement on the employment front, and gradual rise in inflation toward the 2 percent target.
Tech Bubble? Maybe, Maybe Not

Editor’s note: Bill Maris is president and managing partner at Google Ventures.
I’ve heard people wonder if we’re in a bubble with regard to startups. Is it as bad as the 2000 dot-com bubble? Might it actually be worse? I thought it would be worthwhile to look at the available data to see if we can figure this out with more than just a personal opinion. So I asked our engineering team at Google Ventures to dig into the bubble question and find out what the data say. In this post, I’ll share what I learned.
Back in the late 1990s, venture capitalists got very excited about the Internet. A whole lot of money was poured into some companies that failed rather spectacularly, and a lot of people lost a lot of money.
Fast forward to 2015. If you read the headlines about multi-billion-dollar valuations for companies like Uber (one of our portfolio companies), Airbnb and Dropbox, it’s easy to see why some people are feeling antsy. Is everyone irrationally excited about new platforms and economic models in the same way folks were excited in 1999? Or is this different? There are two sides to the case.
The case against a bubble
While the data show that venture investing is increasing, they also illustrate four key differences from the dot-com bubble.
1. Companies are slower to go public
During the 2000 bubble, many companies rushed to go public before they had any revenue. Today, companies are taking longer to IPO:

2. Venture fundraising is way below 2000 peak
In 2000, money flooded into venture capital, and VCs used that money to fund companies that might not otherwise “meet the bar” — resulting in some spectacular failures. Today, VC fundraising is on the uptick, but it’s still far below the 2000 level:

3. Total number of investments is fairly flat
In 2000, VCs made a record number of investments — over 2,000 that year alone. How does that compare to today? It may not feel like it, but the number of VC investments has actually been fairly flat since 2007. This suggests that VCs are still being selective:

4. VCs are investing more money — but only half of 2000 peak
Venture capital investing shot up in 2013 and 2014, but it’s still far short of dot-com bubble levels:

During the bubble in 2000, more VC dollars led to more investments. Today, VC investing is up, but the number of deals is flat. What’s going on? As we’ll see, investors are focusing their money on a relatively small number of large deals.
The case for a bubble
Our data analysis reveals more than sunshine and lollipops. Here are six troubling signs that suggest we may be in another tech bubble.
1. Investors are putting more money into late-stage rounds
If you believe late-stage financing is replacing IPOs for fundraising, this might not be a worrisome sign. Still, it’s easy to see the similarity to 2000:

2. Private company valuations are rising
Until now, our data have shown an environment that is milder than 2000. Today’s valuations tell a different story:

3. Valuations are increasing faster than venture fundraising
Here’s another concerning chart:

4. High-end IPO valuations are rising dramatically
IPO valuations have increased across the board, but the most successful companies are going public at much higher valuations (or perhaps they’re just waiting longer).

5. Late-stage financing is displacing exits
Both late-stage valuations and acquisition price tags are going up. Meanwhile, IPO valuations are going down. Late-stage financing and acquisitions are, in effect, replacing IPOs.

6. Exit ratios are dropping
The data indicate that IPO valuations are not growing as fast as late-stage private company valuations. In fact, if we look at the ratio of IPO valuation to late-stage valuation, we can see that this ratio has been declining since 2009. This suggests that late-stage investors might expect lower returns than in the past.


When we look at the data, only one thing is clear: 2015 is really different from 2000. Some differences are reassuring (e.g. total number of VC investments staying flat), while others are disconcerting (e.g. skyrocketing valuations and declining exit return ratios).
The data clearly show an increase in late-stage financing, but there are a couple ways to interpret this. One hypothesis is that plentiful late-stage financing from VCs and private-equity funds is causing companies to stay private instead of going public or being acquired. Another take is that technology has enabled companies to grow more quickly, and late-stage funding has risen to meet the needs of these young (but large) startups.
The bottom line? If there is a bubble, it’s a different kind of bubble. And this makes sense, because the market and technology landscapes have changed dramatically in the last 15 years.
Of course, companies will still fail, and with today’s huge valuations and the accompanying attention, those failures will seem even bigger and splashier. But that doesn’t mean the sky is falling. When one of these super-valued companies fails — which is inevitable — we’ll have to take a deep breath and ask ourselves whether it’s something endemic or just part of the normal failure rate. Perhaps we should look at the data before pressing the panic button.
Gapping up
In reaction to strong earnings/guidance: WSCI +9.2%, CYCC +6.3%, TRQ +5.5%, AMPH +2.4%, REX +2.4%, SONC +0.4%
M&A news: KFX +45.7% (Lexmark to acquire Kofax), KRFT +34.5% (Kraft Foods and H.J. Heinz Company merge to create The Kraft Heinz Company), FXCM +8.2% (announces intent to sell FXCM Japan to Rakuten Sec for $62 mln STMP +7.2% (to Acquire Endicia From Newell), LXK +7.1% (Lexmark to acquire Kofax)
Select solar stocks trading higher: RGSE +16.2%, ASTI +2.3%, JKS +2% (announced that it will supply 104 MW dc of PV solar panels for the Utah Red Hills Renewable Park project), SOL +1.3%, CSUN +1.1%
Select oil/gas related names showing strength: RIG +2.9%, BP +1.5%, RDS.A +1.5%, SDRL +1.3%
Other news: ONCY +20.4% (announces the receipt of Orphan Drug Status from the European Medicines Agency for REOLYSIN to treat ovarian cancer), VBLT +19.7% (reports interim topline results from Phase 2 clinical trial of VB-111 to treat recurrent glioblastoma), NAVB +8.1% (announces that data from its Lymphoseek injection studies in melanoma, breast and oral cavity squamous cell cancers will be presented will be presented at the 68th Annual Cancer Symposium of the Society of Surgical Oncology), MRNS +6.5% (receives FDA Orphan Drug Designation in PCDH19 female epilepsy), BLRX +5.3% (announces successful top-line results from the Phase 1 safety and efficacy study of its lead clinical candidate),RGLS +3.1% (receives Orphan Medicinal Product Designation from the European Commission for RG-012), CLDN +2.7% ( received Emergency Use Authorization from the FDA for Xpert Ebola, a molecular diagnostic test for Ebola Zaire Virus), AHS +2.5% (favorable commentary on Tuesday's Mad Money), WWAV +2.4% (in symp with KRFT), GIS +2% (in symp with KRFT), RIO +1.8% (in connection with TRQ news), MRK +1.6% (announced new $10 bln share repurchase program)
Analyst comments: GRPN +2.8% (upgraded to Buy from Hold at Wunderlich), NTT +1.4% (upgraded to Overweight from Equal Weight at Barclays), URI +0.9% (initiated with a Outperform at Wells Fargo)
In reaction to strong earnings/guidance: WSCI +9.2%, CYCC +6.3%, TRQ +5.5%, AMPH +2.4%, REX +2.4%, SONC +0.4%
M&A news: KFX +45.7% (Lexmark to acquire Kofax), KRFT +34.5% (Kraft Foods and H.J. Heinz Company merge to create The Kraft Heinz Company), FXCM +8.2% (announces intent to sell FXCM Japan to Rakuten Sec for $62 mln STMP +7.2% (to Acquire Endicia From Newell), LXK +7.1% (Lexmark to acquire Kofax)
Select solar stocks trading higher: RGSE +16.2%, ASTI +2.3%, JKS +2% (announced that it will supply 104 MW dc of PV solar panels for the Utah Red Hills Renewable Park project), SOL +1.3%, CSUN +1.1%
Select oil/gas related names showing strength: RIG +2.9%, BP +1.5%, RDS.A +1.5%, SDRL +1.3%
Other news: ONCY +20.4% (announces the receipt of Orphan Drug Status from the European Medicines Agency for REOLYSIN to treat ovarian cancer), VBLT +19.7% (reports interim topline results from Phase 2 clinical trial of VB-111 to treat recurrent glioblastoma), NAVB +8.1% (announces that data from its Lymphoseek injection studies in melanoma, breast and oral cavity squamous cell cancers will be presented will be presented at the 68th Annual Cancer Symposium of the Society of Surgical Oncology), MRNS +6.5% (receives FDA Orphan Drug Designation in PCDH19 female epilepsy), BLRX +5.3% (announces successful top-line results from the Phase 1 safety and efficacy study of its lead clinical candidate),RGLS +3.1% (receives Orphan Medicinal Product Designation from the European Commission for RG-012), CLDN +2.7% ( received Emergency Use Authorization from the FDA for Xpert Ebola, a molecular diagnostic test for Ebola Zaire Virus), AHS +2.5% (favorable commentary on Tuesday's Mad Money), WWAV +2.4% (in symp with KRFT), GIS +2% (in symp with KRFT), RIO +1.8% (in connection with TRQ news), MRK +1.6% (announced new $10 bln share repurchase program)
Analyst comments: GRPN +2.8% (upgraded to Buy from Hold at Wunderlich), NTT +1.4% (upgraded to Overweight from Equal Weight at Barclays), URI +0.9% (initiated with a Outperform at Wells Fargo)
Kraft Foods: Heinz Merger Conference Call
* Will refi almost all of Heinz' high cost debt; will call existing Heinz preferred equity to use new investment grade debt
* Will save approx $450 mln annually.
* Looking to reduce net leverage to below 3%;
* Will not conduct share repurchases for at least two years as it tackles debt issues first.
Assume $62.24 prior 20 day VWAP (pre-deal multiples), $16.50 special dividend, $1,000M synergies (attributed to KFRT) and 30% tax rate. Implied KRFT valuation is $81-$82 (P/F EBITDA) and $84-$85 (P/F P/E).
Berkshire Hathaway's Buffett: Will will have three board seats and 320M common shares or about $9.5B in the new Kraft-Heinz, will hold the shares forever
